166 related articles for article (PubMed ID: 38074651)
1. Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone.
Zhao YY; Xiong ML; Liu YF; Duan LJ; Chen JL; Xing Z; Lin YS; Chen TH
Front Oncol; 2023; 13():1247682. PubMed ID: 38074651
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions.
Hectors SJ; Chen C; Chen J; Wang J; Gordon S; Yu M; Al Hussein Al Awamlh B; Sabuncu MR; Margolis DJA; Hu JC
J Magn Reson Imaging; 2021 Nov; 54(5):1466-1473. PubMed ID: 33970516
[TBL] [Abstract][Full Text] [Related]
3. Utility of Clinical-Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions.
Jin P; Yang L; Qiao X; Hu C; Hu C; Wang X; Bao J
Front Oncol; 2022; 12():840786. PubMed ID: 35280813
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters.
Woźnicki P; Westhoff N; Huber T; Riffel P; Froelich MF; Gresser E; von Hardenberg J; Mühlberg A; Michel MS; Schoenberg SO; Nörenberg D
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630787
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
Front Oncol; 2021; 11():825429. PubMed ID: 35155214
[TBL] [Abstract][Full Text] [Related]
6. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study.
Jin P; Shen J; Yang L; Zhang J; Shen A; Bao J; Wang X
BMC Med Imaging; 2023 Mar; 23(1):47. PubMed ID: 36991347
[TBL] [Abstract][Full Text] [Related]
7. [The value of machine learning models based on biparametric MRI for diagnosis of prostate cancer and clinically significant prostate cancer].
Qiao XM; Hu CH; Hu S; Hu CH; Wang XM; Shen JK; Ji LB; Song Y; Bao J
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1446-1454. PubMed ID: 37198106
[No Abstract] [Full Text] [Related]
8. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
10. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
11. A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions.
Hou Y; Bao ML; Wu CJ; Zhang J; Zhang YD; Shi HB
Abdom Radiol (NY); 2020 Dec; 45(12):4223-4234. PubMed ID: 32740863
[TBL] [Abstract][Full Text] [Related]
12. Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL.
Lu Y; Li B; Huang H; Leng Q; Wang Q; Zhong R; Huang Y; Li C; Yuan R; Zhang Y
Front Oncol; 2022; 12():1020317. PubMed ID: 36582803
[TBL] [Abstract][Full Text] [Related]
13. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
14. Performance variability of radiomics machine learning models for the detection of clinically significant prostate cancer in heterogeneous MRI datasets.
Gresser E; Schachtner B; Stüber AT; Solyanik O; Schreier A; Huber T; Froelich MF; Magistro G; Kretschmer A; Stief C; Ricke J; Ingrisch M; Nörenberg D
Quant Imaging Med Surg; 2022 Nov; 12(11):4990-5003. PubMed ID: 36330197
[TBL] [Abstract][Full Text] [Related]
15. Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer.
Krauss W; Frey J; Heydorn Lagerlöf J; Lidén M; Thunberg P
Acta Radiol; 2024 Mar; 65(3):307-317. PubMed ID: 38115809
[TBL] [Abstract][Full Text] [Related]
16. MRI-Based Surrogate Imaging Markers of Aggressiveness in Prostate Cancer: Development of a Machine Learning Model Based on Radiomic Features.
Dominguez I; Rios-Ibacache O; Caprile P; Gonzalez J; San Francisco IF; Besa C
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685317
[TBL] [Abstract][Full Text] [Related]
17. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
18. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
[TBL] [Abstract][Full Text] [Related]
19. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
20. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
